NCT04356170View on ClinicalTrials.gov

Trial Evaluating Adapted Chemotherapy in Patients With Squamous Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

February 4, 2021

Primary Completion Date

August 5, 2025

Study Completion Date

August 5, 2025

Conditions
Cancer of Head and Neck
Interventions
DRUG

Docetaxel

Docetaxel 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour

DRUG

Cisplatin

cisplatine 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour

DRUG

Fluoro Uracil

750 mg/m²/j administered continuously at D1 to D5 of each cure, every 3 weeks by intravenous infusion ( so 120 hours)

Trial Locations (1)

69008

Centre Leon Berard, Lyon

All Listed Sponsors
collaborator

Centre Leon Berard

OTHER

lead

Groupe Oncologie Radiotherapie Tete et Cou

OTHER

NCT04356170 - Trial Evaluating Adapted Chemotherapy in Patients With Squamous Carcinoma | Biotech Hunter | Biotech Hunter